Microneedle Sensor Tracks Drug Clearance, Organ Issues

Got story updates? Submit your updates here. ›

Wearable sensors that use microneedles to painlessly take samples at skin level could help personalize health care and enable precision drug dosing in real time, but many have been limited by weak signals and damage caused by friction in tissue. A UCLA-led team developed a microneedle platform that operated continuously for six days in rats while improving signal quality and resistance to abrasion. In preclinical studies, the technology not only tracked drug levels but also revealed impaired kidney and liver function based on how quickly drugs cleared from the animals' systems — including identifying early kidney injury before conventional blood tests indicated a problem.

Why it matters

Wearable technologies are starting to reshape how people manage health, with continuous glucose monitors already showing the power of tracking an important molecule in real time. The next leap is to track other medically important molecules, which is more difficult due to their much lower concentrations. This could transform drug therapy, where clinicians often only get occasional snapshots of how a patient's body is processing treatment, missing the point when dosing becomes ineffective or begins to threaten the organs responsible for processing the drug.

The details

The UCLA-led research team developed a microneedle sensor platform designed for continuous, minimally invasive monitoring in skin. The sensors' design protects the sensing molecules while greatly increasing the microneedle's sensitivity through a strongly adhered gold coating with nanoscale cavities. This helps extend sensor operation from only hours to six days in freely moving rats and dramatically expands the active area available for detection. In preclinical experiments, the researchers used the microneedles to track two drugs - a chemotherapy processed by the liver and an antibiotic cleared by the kidneys - and were able to infer organ function by continuously monitoring how drug levels rose and fell.

• In one experiment, the team followed animals through two weeks of worsening kidney dysfunction and then two weeks of treatment intended to stimulate recovery.
• The researchers found that during the first week of kidney injury, the microneedle measurements already indicated impaired drug clearance, while blood creatinine - the conventional biomarker used to assess kidney function - remained below thresholds signaling injury.

What they’re saying

What’s next

The researchers next aim to move the technology toward human studies to determine whether this kind of monitoring can help prevent damage from antibiotics and chemotherapies by recognizing trouble earlier and adjusting treatment sooner.